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ABSTRAK
Latar  Belakang:  Congenital  Adrenal  Hyperplasia (CAH)  merupakan  DSD yang 
paling banyak ditemukan pada 46,XX dan muncul jika terjadi defisiensi pada salah 
satu dari enzim yang dibutuhkan untuk sintesis cortisol dan aldosteron di kelenjar 
adrenal,  sehingga terjadi ketidakseimbangan hormon adrenal.  Terapi  sulih  hormon 
dengan  menggunakan  hidrokortison  adalah  salah  satu  cara  untuk  mengontrol 
keseimbangan  hormon  adrenal.  Untuk  memonitor  keefektivitasan  terapi  ini, 
diperlukan  pengukuran  prekursor  hormon  adrenal  (17OHP  dan  androstenedione). 
Selain  itu,  setiap  terapi  dapat  menyebabkan  efek  samping  yang  perlu  dikontrol. 
Tujuan dari penilitian ini adalah untuk mencari perbedaan kadar hormone sebelum 
dan sedudah terapi dan mencatat efek samping.
Metode: Desain  pre-eksperimental  dengan  satu  kelompok  pre  tes  dan  post  tes 
dilakukan  untuk  mengobservasi  kadar  17OHP  dan  androstenedione.  Penelitian 
terhadap efek samping terapi hidrokortison menggunakan analisis deskriptif. Sample 
pada penelitian ini adalah setiap pasien CEBIOR yang terdagnosis CAH secara klinis, 
sitogenetika,  dan  hormonal  dan  atau  analisis  mutasi  pada  gen CYP-21  kemudian 
menerima  terapi  hidrokortison  dan  pengontrolan  terapi.  Sampel  plasma  darah 
digunakan sebagai  material  pre-terapi  dan saliva digunakan sebagai  material  post-
terapi,  kemudian  dianalisis  menggunakan  ELISA  Hormonal  data  dianalisis 
menggunakan  uji  Wilcoxon.  Data  efek  samping  dipresentasikan  dengan  narasi 
deskriptif.
Hasil: Analisa  Wilcoxon dengan  membandingkan  data  pre  dan  post  terapi 
menghasilkan  penurunan dengan p=0.987 untuk 17-OHP and peningkatan  dengan 
p=0.04 untuk androstenedione. Terdapat 12 subjek dengan perawakan pendek setelah 
terapi  hidrokortison  dan  beberapa  dari  mereka  menyampaikan  keluhan  penyerta. 
Keluhan penyerta terbanyak adalah dehidrasi (44.44% dari keluhan total).
Simpulan: Perbandingan antara 17-OHP pre dan post terapi menunjukkan penurunan 
yang tidak signifikan,  sedangkan pada androstenedione  terdapat  peningkatan  yang 
signifikan. Penyebab efek samping terbanyak adalah dosis terapi yang tidak adekuat.
Kata  kunci:  congenital  adrenal  hyperplasia,  CAH,  hidrokortison,  17-OHP, 
androstenedione, efek samping
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ABSTRACT
Background:  Congenital Adrenal Hyperplasia (CAH) is the most common 46,XX 
DSDs, which occurred when one of the enzymes required for cortisol and aldosterone 
synthesis in adrenal gland is deficit, therefore performed adrenal hormone imbalance. 
Hormone replacement therapy using hydrocortisone is an option that allows control 
of the adrenal hormones balance. To monitor the effectiveness of therapy, measuring 
the  adrenal  hormones  precursors  (17-OHP  and  androstenedione)  is  required. 
Nevertheless, every therapy has side effect that must be controlled. The aim of this 
research is to seek 17-OHP and androstenedione levels post- compared to pre-therapy 
and also side effect of hydrocortisone therapy.
Methode: A pre-experimental study with one group pretest-posttest design was done 
to observe 17-OHP and androstenedione levels. The side effect post hydrocortisone 
therapy used a descriptive study. Samples of this research were all patients recorded 
in CEBIOR which are diagnosed as CAH after the clinical, cytogenetic and hormonal 
check-up and/or after the CYP21-gene mutation analysis then receive hydrocortisone 
therapy and follow-up. Blood plasma sample  for hormonal  pre-therapy and saliva 
sample for hormonal post therapy were analyzed using ELISA. This hormonal data 
was  analyzed  Wilcoxon test.  Side  effect  data  were  presented  in  a  descriptive 
narration.
Result: 38  cases  (12.88%)  of  DSDs  were  registered  in  CEBIOR,  and  23  were 
suitable to inclusion criteria.  Wilcoxon  analysis by comparing pre and post therapy 
hormonal data showed decline with p=0.987 for 17-OHP and elevation with p=0.04 
for androsetedione. There were twelve subjects with short stature after hydrocortisone 
therapy  and  some  of  them  complained  intercurrent  illness.  The  most  common 
intercurrent illness was dehydration (44.44% of total complain).
Conclusion: Comparison between 17-OHP pre and post  therapy is  insignificantly 
decreased, whereas in androstenedione there is significant elevation. Side effects of 
hydrocortisone therapy are frequently caused by inadequate doses.
Keywords:  congenital  adrenal  hyperplasia,  CAH,  hydrocortisone,  17-OHP, 
androstenedione, side effect
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INTRODUCTION
Congenital Adrenal Hyperplasia (CAH), which is classified as Disorders of 
Sex Development (DSDs), is usually diagnosed due to ambiguous genitalia  in the 
newborn.1 Mostly, the patients are genetically female (46,XX) with virilization. This 
disorder is occurred when one of the enzymes required for cortisol and aldosterone 
synthesis in adrenal gland is deficit.2,3 The condition results to hyperplasia of adrenal 
and stimulation of hormone precursors, such as 17-hydroxyprogesterone (17-OHP) 
and androstnenedione, thus leads to elevation of testosterone level.3,4
In Medical Faculty of Diponegoro University/Dr. Kariadi Hospital Semarang, 
CAH  cases  are  managed  by  gender  adjustment  team,  after  the  diagnostic  and 
therapeutic  processes.  Treatment  for  CAH patients  is  to provide adequate adrenal 
hormones substitution to prevent adrenal crises and to suppress excess adrenocortical 
testosterone production.5 Hormone replacement therapy using hydrocortisone is an 
option that allows control of the adrenal hormones balance.
To  monitor  the  effectiveness  of  therapy,  measuring  the  adrenal  hormones 
precursors is required. Nevertheless, every therapy, including hydrocortisone therapy, 
has side effect  that  must  be controlled.  However,  research in hormone precursors 
features post hydrocortisone therapy and also side effect of this therapy in Semarang 
has never been done.
The aim of this research is to seek the 17-OHP and androstenedione levels, as 
well  as  side  effect  post  hydrocortisone  therapy  of  CAH  patients  to  get  better 
understanding of hydrocortisone therapy and also can be useful in further researches 
about CAH. This research also can provide information for the patients about the 
effectiveness of their therapy.
METHODS
Subjects  for  this  research  were  all  patients  confirmed  as  CAH  after  clinical, 
cytogenetic  and  hormonal  examination  and/or  mutation  analysis  and  received 
hydrocortisone therapy and follow-up. This research was using a secondary data from 
medical records of CAH patients during period 2004 – July 2010. Data was obtained 
from physical examination, cytogenetic, hormonal work-up and mutation analysis.
This research was a pre-experimental study with one group pretest-posttest 
design  to  observe  the  17-OHP  and  androstenedione  levels.  The  side  effect  post 
hydrocortisone therapy of CAH patients used the descriptive method. This research 
was  conducted  at  Center  of  Biomedical  Research (CEBIOR) of  Medical  Faculty 
Diponegoro University / Dr. Kariadi Hospital Semarang.
In this study, after clinically diagnosed as CAH, blood sample was taken for 
cytogenetic, hormonal data pre therapy and mutation analysis. CAH patients under 17 
years  old  received  hydrocortisone  therapy  at  the  dose  10-12mg/m2/day  with 
readjustment  of  doses  when needed.  Follow-up data  was required  to  monitor  the 
therapy,  thus saliva sampling using Salivette® was done every three months after 
hydrocortisone achieved for hormonal work-up. Both pre and post therapy hormonal 
work-up were analyzed using ELISA. Side effect data was also noted every three 
months  when  the  patients  come  for  follow-up.  All  examinations  were  done  at 
CEBIOR,  except  initial  hormonal  data  and  mutation  analysis  were  done  in  The 
Netherland.
Data  processing  on  17-OHP  and  androstenedione  were  analyzed  using 
Wilcoxon  test. Side effect data was reported using descriptive method. Tables and 
charts were presented to show the result.
RESULTS
Of all 40 patients suspected as CAH, only 38 left diagnosed as CAH after 
further examination. Furthermore fifteen of patients are excluded from this research 
due to reject  follow-up (n=3),  lost  contact  (n=4),  not medicated (n=5),  treated by 
prednisone (n=1), and hormonal post therapy has not been analyzed (n=2). Thus, total 
subject used in this research was 23.
From 23 subjects, mean of initial age at presentation was 4.948. All of the 
subjects  were female,  except  one male  and one undecided.  Eighteen  subjects  had 
done DNA analysis and showed the mutation of DNA. Characteristic of the data can 
be seen in table below.
Table 1. Characteristic of Data
Number of Subjects 23  
Initial Age 4.948±4.770  
Minimum 0.02
Maximum 15.65
Before 2009 6.026±4.535
2009 1.896±4.379
Gender
Male 1 4.35%
Female 21 91.30%
Undecided 1 4.35%
Gender classified by Karyotype
46,XX 21 91.30%
Female 20 86.96%
Undecided 1 4.35%
46,XY (all male) 1 4.35%
46,XX (99%)/46,XY (1%) (all 
female) 1 4.35%
Quigley Stage
0 (normal male) 1 4.35%
1 0 0.00%
2 1 4.35%
3 12 52.17%
4 5 21.74%
5 2 8.70%
6/7 (normal female) 2 8.70%
Mutation
CYP21 16 69.57%
CYP11B2 2 8.70%
not yet analyzed 5 21.74%
Subjects  in  this  study  received  hydrocortisone  therapy.  They  had  done 
hormonal examination pre and post therapy. The aim of post therapy hormonal check-
up  was  monitor  hydrocortisone  therapy.  The  first  four  times  of  follow  up  are 
presented in the charts below.
Figure 1. 17-Hydroxyprogesterone Follow-up
Figure 2. Androstenedione Follow-up
The most recent hormonal data is also performed in this study compared to 
initial  data  that  was taken before  therapy.  The comparison  between pre  and post 
therapy were analyzed using Wilcoxon test. Table 2 shows the result of Wilcoxon test.
Table 2. Wilcoxon test for 17-OHP and androstenedione pre-post therapy
Initial Post Therapy P
17-Hydroxyprogesterone 876.405±949.968 759.972±407.618 0.987
Androstenedione 132.248±131.279 325.577±286.592. 0.004
The side effect of hydrocortisone therapy was also noted. Data included the 
growth of  the  subjects  pre  and post  therapy,  and also  intercurrent  illness.  Of  23 
subjects, twelve were short stature. Table 3 shows the side effect of hydrocortisone 
therapy on the subjects.
Table 3. Side Effect Data
Subj. 
No. Initial Age
Pre 
Therapy: 
Short 
Stature
Post 
Therapy: 
Short 
Stature
Intercurrent 
Illness Remarks
3 10.53 no Yes Sp ID*
5 9.78 no Yes D ID*
7 6.56 no No - NH
9 7.45 no Yes - ID*
10 4.25 no No - NH
12 19.23 m.o yes No - NH/U*#
15 2 m.o yes No - NH
17 10.22 yes Yes - SS**
18 3.55 no (tall) no (tall) - NH
19 9.98 no (tall) No Sp NH
21 5.94 no No - NH
24 7.77 no No - NH
25 15.65 yes Yes - SS/OD
26 11.67 no (nearly) No - NH
29 4.01 no No - NH*
31 4.87 no (tall) No - NH*
32 0.57 m.o no Yes - U*#
33 2.83 m.o yes Yes - SS
34 1.07 m.o yes Yes d† SS*#
35 1.07 m.o yes Yes o, sp SS*
36 10.83 yes Yes - SS*
37 1.40 m.o no (nearly) Yes d† SS*
38 0.27 m.o no (nearly) Yes d,o ID*
d  :  dehydration  (vomiting,  diarrhea);  sp  :  skin  problem  (dermatitis,  itch,  vulnus 
excoriatum); o : other (cough, cold); † : died
ID : inadequate doses; OD : overdoses; SS short stature from the beginning; NH : normal 
height; U : unclassified, * : bad hormonal response; ** : very bad hormonal response; # :  
only once followed-up
DISCUSSION
From 2004 to July 2010, 295 patients are recorded as DSDs patients at Center 
of Biomedical Research (CEBIOR), and 38 cases (12.88% of DSDs) confirmed as 
CAH after clinical, cytogenetic and hormonal check-up and/or mutation analysis. In 
North  Indian,  CAH (36.2%) was  the  most  common  cause  among  DSDs (n=58).6 
Great difference number between DSDs cases at  CEBIOR and in that research in 
North Indian may result in different percentage of CAH and other DSDs cases.
CAH patients were varied in the ages at presentation. Before 2009 initial ages 
of CAH patients were varied in prepuberty,  puberty and even adults,  whereas the 
promptly diagnosis and treated of CAH is very important to prevent death in early 
infancy from Addisonian crisis. But in 2009, due to better information to medical and 
public communities, CAH cases in infants and even neonates became more reachable.
CAH  were  usually  diagnosed  due  to  virilization  of  external  genitalia  in 
genetically female (46,XX) patients. As we can see the most Quigley Stage present in 
the patients with CAH at CEBIOR is 3 (Quigley Stage for normal male is 0, while for 
normal  female  are  6  to  7).  Two  patients  with  initial  Quigley  Stage  6  had  been 
operated before examined themselves.
Interestingly, there was a genetically male (46,XY) CAH patient. This male 
patient  was  diagnosed  due  to  severe  dehydration,  which  is  typically  salt-wasting 
CAH. On the other hand, of 21 cases of CAH in North Indian, fifteen were 46,XY. 
There was excess genetically males there, possibly due to frequent male gender.6
Five of all CAH patients at CEBIOR were not treated. Three of which chose 
to  be  male,  thus  they  do  not  require  maintenance  therapy  to  reduce  testosterone 
excess. The other two have normal hormonal levels from the beginning, but they both 
have ambiguous external genitalia and mutation on CYP21 gene, therefore diagnosed 
as CAH. In other research, two infants also confirmed as CAH with normal level of 
17-OHP and both had CYP21 mutation. One patient carried the L30 nonclassic allele, 
the other had a classic CYP21 null genotype with ambiguous genitalia phenotype.7
Subjects of this research had done hormonal analysis pre and post therapy. 
The  most  recent  17-hydroxyprogesterone  and  androstenedione  were  compared  to 
initial data. The decline on 17-OHP levels from initial data to post therapy were not 
significant statistically (p=0.987). From 22 subjects (one was missing), eleven were 
declined,  and  eleven  were  elevated.  An  odd  significantly  elevated  (p=0.004)  of 
androstenedione were performed in this study. Research in Turkey shows declined of 
17-OHP and androstenedione levels  in 100% subjects  (n=11) after  hydrocortisone 
therapy.8 The  different  result  may  be  caused  by  several  reason  that  would  be 
explained below.
Pre  therapy  data  in  this  study  were  measured  using  blood  plasma  as  the 
material  and  analyzed  using  ELISA  in  The  Netherlands  with  high  sensitivity  of 
ELISA-kit. The follow-up data were measured using saliva as the sample and also 
analyzed using ELISA at CEBIOR. The ELISA-kit for saliva has weaker sensitivity 
and can only detect up to 1 000 pg/mL, but saliva analyzing method is still able to 
reach  the  therapeutic  goal  range  (100–1  000  ng/dL=10–100  pg/mL).3 Many 
researches show strong correlation between 17-OHP and androstenedione in plasma 
and saliva.9-11 Saliva is also an accepted non-invasive method, therefore saliva sample 
is good for follow-up the therapy, but could not shows the true decline or elevation 
with the real values that may influence the result.
Interestingly, in  this  result  was  that  17-OHP and androstenedione  showed 
different condition statistically.  Whereas, the majority of studied have shown good 
correlation  between 17-OHP and  androstenedione  concentration  in  single  sample, 
indicating  that  this  hormones  concentration  are  both  under  similar  influence.10 In 
addition, pre therapy data were received in nmol/L (SI unit), and post therapy data 
were presented  in  pg/mL (conventional  unit).  Pre therapy data  were converted  to 
pg/mL  (conversion  factor  from  conventional  units  to  SI:  17-OHP=0.3026; 
Androstenedione=0.349)12  Therefore,  error  in  converting  may  also  influence  the 
result.
The result may also occur due to non compliance of the subject. They used to 
consume the medication three times a day, but some of them admitted that sometimes 
they  missed  a  therapy.   In  a  new  research  using  pharmacokinetic  and 
pharmacodynamic  study  shows  that  modified-release  hydrocortisone  (MR-HC) 
represents a promising new treatment for CAH to substitute existing glucocorticoid 
treatment hydrocortisone (HC).13 In 14 subjects of that research,  one week of thrice 
daily HC (10, 5 and 15 mg) was followed by one month of once daily MR-HC (30 
mg at 22:00 hours). The outcomes were more fluctuated when using HC than MR-
HC. No serious adverse effect  was noted using MR-HC and they merely have to 
consume the medication once a day.
We found polymorphism in the subjects at CEBIOR. The mutation that shows 
salt-wasting phenotype in subjects of previous researches occurred as only simple 
virilization in the subjects at CEBIOR. It may also influence the effectiveness of the 
therapy.
The result was unexpected, therefore the hormonal charts were presented to 
show the real condition. The charts showed fluctuated post therapy data in the first 
four times of follow-up. Subjects who showed elevation from pre to post therapy 
statistically,  ever  showed decline  in  some follow-up.  The subjects  in  this  therapy 
sometimes came after one week or more after the last medication. They may show the 
elevated result, when they came late.
Besides  providing  adequate  substitution  of  glucocorticoid  and 
mineralocorticoid and also suppression of adrenal androgen by controlling the 17-
OHP and androstenedione levels,  the other therapeutic  goal is to maintain normal 
growth which can be defined by normal height at  prepuberty,  puberty and adults. 
Comparing the hormonal data to the growth was also helpful to show the condition in 
each  patient. There  were  twelve  subjects  with  short  stature.  Short  stature  is  an 
unwanted effect of the therapy that can be caused by inadequate doses, overdoses and 
also  premature  closure  of  ephiphyseal  plate  due to  high  testosterone  level  before 
receiving  therapy.  Patients  with  inadequate  doses  usually  complained  intercurrent 
illness due to electrolyte imbalance, such as dehydration that can be life-threatening 
adrenal  crisis14,  while  overdoses  should  have  maintained  the  electrolyte  balance. 
Overdoses usually show normal to low hormonal level after therapy. Therefore, to 
classify  the  samples  into  patient  with  inadequate  doses,  overdoses,  and had high 
testosterone level before receiving therapy, we need to see initial stature, post therapy 
stature,  intercurrent  illness,  and also hormonal  data of the patients.  Some patients 
with only one hormonal data in follow-up were hardly classified.
Five of the subjects with short stature were not short when they checked up 
for the first  time and had high hormonal  values  in follow up. Most of them also 
complained intercurrent illness. They can be classified as patients with inadequate 
doses, except one with mere follow-up data (subject 32) cannot be classified. Of four 
patients with inadequate doses, one is a 46,XY salt-wasting type baby with severe 
intercurrent  illness  (subject  no.  38).  Normally,  male  do  not  receive  any 
hydrocortisone treatment to suppress adrenal androgen, but in this case, this subject 
needs hydrocortidone to suppress the dose of fludrocortisones needed due to severe 
dehydration. But it still cannot reduce the severity of intercurrent illness, probably 
due to inadequate doses.
Seven subjects were short stature from the beginning. At diagnosis time, three 
of them were in the age of puberty. Two of which had high hormonal level (subj no. 
36 & 17). Thus the short stature may caused by uncontrolled testosterone level before 
therapy.  One subject which was puberty at presentation had a good and even low 
hormonal  value  (subject  no.  25).  Before  came to  CEBIOR this  subject  had  been 
treated. Therefore this subject may be classified to overtreatment. The other four were 
still infants at presentation until the recent follow-up, therefore the normal height for 
them are probably below the percentile curve in the chart. Furthermore, the chart used 
was taken from Centers of Disease Control and Prevention (CDC), United States.15 
Indonesian people may have different range of normal height.
Two subjects with normal height had bad hormonal value, but both of them 
cannot be classified because only one follow-up data performed. One other subject 
with normal  data complained skin problem (acne),  but  the hormonal  is  still  good 
control. Acne may also be caused by other than androgen excess.16
Insignificant  Reduction  of  17-hydroxyprogesterone  level  (p=0.987)  and 
significant  elevation  of  androstenedione  (p=0.004)  from  initial  data  of 
androstenedione to post hydrocortisone therapy are performed in this study, which is 
not expected and may caused primary by inadequate doses due to non compliance, 
polymorphism of mutation and late coming for follow-up.
Side effects occurred were dehydration (44.44%), skin problem (33.33%) and 
others include cold and cough (22.22%). After analyzed, it mostly occurred due to 
inadequate doses that may lead to failure in therapy thus hormonal condition is not 
decline as in the hypothesis.
The difference between sample of pre and post therapy and the number of 
samples are suggested as factors which may affect the result. For further research, it 
will be good to use the same samples for pre and post hormonal therapy in either in 
blood  or  saliva  with  greater  sample  of  research.  Determining  the  optimal  dosing 
regimen and long-term clinical outcome of MR-HC is also needed for further studies.
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